Literature DB >> 25993910

Reirradiation for second primary or recurrent cancers of the head and neck: Dosimetric and outcome analysis.

Shivank Garg1, Jeremy M Kilburn1, John T Lucas1, David Randolph1, James J Urbanic1, William H Hinson1, William T Kearns1, Mercedes Porosnicu2, Kathryn Greven1.   

Abstract

BACKGROUND: The purpose of this study was to examine outcomes, toxicity, and dosimetric characteristics of patients treated with reirradiation for head and neck cancers.
METHODS: Fifty patients underwent ≥2 courses of radiation therapy (RT) postoperatively or definitively with or without chemotherapy. Composite dose volume histograms (DVHs) for selected anatomic structures were correlated with grade ≥3 late toxicity.
RESULTS: Median initial and retreatment radiation dose was 64 and 60 Gy, respectively. Median overall survival (OS), progression-free survival (PFS), and 1-year PFS rates were 18 months, 11 months, and 45%, respectively, with 13 months median follow-up. Thirty-four percent of patients experienced grade ≥3 late toxicity with 1 death from carotid blowout. The DVH corresponding to the carotid blowout fell above the third quartile compared with other patients.
CONCLUSION: Our analysis is the first to systematically evaluate the dose to the carotid artery using composite dosimetry in head and neck reirradiation patients, and demonstrates a promising technique for evaluating the dose to other normal tissue structures.
© 2015 Wiley Periodicals, Inc. Head Neck 38: E961-E969, 2016. © 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  blowout; carotid arteries; dosimetry; head and neck; reirradiation

Mesh:

Year:  2015        PMID: 25993910      PMCID: PMC9176709          DOI: 10.1002/hed.24136

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.821


  21 in total

1.  Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma.

Authors:  Joseph K Salama; Everett E Vokes; Steven J Chmura; Michael T Milano; Johnny Kao; Kirsten M Stenson; Mary Ellyn Witt; Daniel J Haraf
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-10-05       Impact factor: 7.038

2.  Reirradiation with intensity-modulated radiotherapy in recurrent head and neck cancer.

Authors:  Felix Zwicker; Falk Roeder; Henrik Hauswald; Christian Thieke; Carmen Timke; Wolfgang Schlegel; Juergen Debus; Marc W Münter; Peter E Huber
Journal:  Head Neck       Date:  2011-01-31       Impact factor: 3.147

3.  Risk factors for developing a second upper aerodigestive cancer after radiotherapy with or without chemotherapy in patients with head-and-neck cancers: an exploratory outcomes analysis.

Authors:  Daniel Taussky; Kaspar Rufibach; Pia Huguenin; Abdelkarim S Allal
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-07-01       Impact factor: 7.038

Review 4.  Locally recurrent, previously irradiated head and neck cancer: concurrent re-irradiation and chemotherapy, or chemotherapy alone?

Authors:  Stuart J Wong; Mitchell Machtay; Yi Li
Journal:  J Clin Oncol       Date:  2006-06-10       Impact factor: 44.544

5.  Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501).

Authors:  Jacques Bernier; Jay S Cooper; T F Pajak; M van Glabbeke; J Bourhis; Arlene Forastiere; Esat Mahmut Ozsahin; John R Jacobs; J Jassem; Kie-Kian Ang; J L Lefèbvre
Journal:  Head Neck       Date:  2005-10       Impact factor: 3.147

6.  Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group Study E1393.

Authors:  A A Forastiere; T Leong; E Rowinsky; B A Murphy; D R Vlock; R C DeConti; G L Adams
Journal:  J Clin Oncol       Date:  2001-02-15       Impact factor: 44.544

Review 7.  Risk of carotid blowout after reirradiation of the head and neck: a systematic review.

Authors:  Mark W McDonald; Michael G Moore; Peter A S Johnstone
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-05-05       Impact factor: 7.038

8.  Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck.

Authors:  Sharon A Spencer; Jonathan Harris; Richard H Wheeler; Mitchell Machtay; Christopher Schultz; William Spanos; Marvin Rotman; Ruby Meredith; Kie-Kian Ang
Journal:  Head Neck       Date:  2008-03       Impact factor: 3.147

9.  Results of postoperative reirradiation for recurrent or second primary head and neck carcinoma.

Authors:  Nicolien Kasperts; Ben J Slotman; C Rene Leemans; Remco de Bree; Patricia Doornaert; Johannes A Langendijk
Journal:  Cancer       Date:  2006-04-01       Impact factor: 6.860

10.  Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911.

Authors:  Corey J Langer; Jonathan Harris; Eric M Horwitz; Nicos Nicolaou; Merrill Kies; Walter Curran; Stuart Wong; Kian Ang
Journal:  J Clin Oncol       Date:  2007-10-20       Impact factor: 44.544

View more
  3 in total

1.  SBRT Treatment of Multiple Recurrent Auricular Squamous Cell Carcinomas Following Surgical and Conventional Radiation Treatment Failure.

Authors:  Drew Brotherston; Ian Poon
Journal:  Cureus       Date:  2015-09-17

2.  Reirradiation of head and neck cancer: Long-term disease control and toxicity.

Authors:  Wouter T C Bots; Sven van den Bosch; Ellen M Zwijnenburg; Tim Dijkema; Guido B van den Broek; Willem L J Weijs; Lia C G Verhoef; Johannes H A M Kaanders
Journal:  Head Neck       Date:  2017-03-06       Impact factor: 3.147

3.  Re-irradiation of canine non-lymphomatous nasal tumours using stereotactic radiation therapy (10 Gy x 3) for both courses: Assessment of outcome and toxicity in 11 dogs.

Authors:  Tracy L Gieger; Siobhan M Haney; Michael W Nolan
Journal:  Vet Comp Oncol       Date:  2022-02-13       Impact factor: 2.385

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.